The influence of age at exposure to PBBs on birth outcomes

Anne M Sweeney1, Elaine Symanski

  • 1Department of Epidemology and Biostatistics, School of Rural Public Health, Texas A&M University System Health Science Center, TAMU Mail Stop 1266, College Station, TX 77843-1266, USA. amsweeney@srph.tamhsc.edu

Insights

Early exposure to polybrominated biphenyls (PBBs) in females under 10 years old is linked to higher infant birth weight. Higher PBB levels also correlated with increased birth weight, highlighting critical exposure windows.

Area of Science:

  • Environmental Health
  • Toxicology
  • Reproductive Health

Background:

  • Critical windows of susceptibility to environmental chemical exposures are a major public health concern.
  • Polybrominated biphenyls (PBBs) are persistent organic pollutants with potential health effects.

Purpose of the Study:

  • To examine the association between early age at exposure to PBBs and subsequent birth weight and gestational length in offspring.
  • To identify critical windows of susceptibility to PBB exposure in relation to reproductive outcomes.

Main Methods:

  • A cohort study of 1111 births from 560 women in the Michigan PBB Cohort (1975-1994).
  • Maternal age at exposure categorized into <10, 11-16, and 17-42 years.
  • Mixed-effects linear regression models used to assess PBBs' effect on birth weight and gestational age, controlling for covariates.

Main Results:

  • Exposure to PBBs at age <10 years was associated with increased birth weight (225 g, P=0.012) compared to older exposure groups.
  • Each 10 ppb increase in serum PBBs correlated with a 16 g increase in infant birth weight (P=0.004).
  • No significant association found between PBB levels and gestational age, or between PCB levels and birth outcomes.

Conclusions:

  • Early age at PBB exposure, particularly before age 10, is a significant predictor of increased birth weight.
  • These findings support the hypothesis that early exposure to environmental chemicals can determine subsequent health effects.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Longitudinal Research02:20

Longitudinal Research

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...